ISOFOL — Isofol Medical AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK306.72m
- SEK210.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.94 | ||
| Price to Tang. Book | 3.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.07% | ||
| Return on Equity | -43.62% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 37.12 | 22.41 | 12.8 | 0.72 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Directors
- Par-Ola Mannefred CHM (58)
- Jarl Jungnelius CEO (70)
- Gustaf Albert CFO
- Roger Tell CSO
- Karin Ganlov OTH (55)
- Anna Belfrage DRC (59)
- Magnus Bjorsne DRC
- Paula Boultbee DRC (62)
- Alain Herrera DRC (69)
- Robert Marchesani DRC
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 16th, 2008
- Public Since
- April 4th, 2017
- No. of Shareholders
- 14,050
- No. of Employees
- 5
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 161,515,440
- Address
- Biotech Center, Arvid Wallgrens Backe 20, GOETEBORG, 413 46
- Web
- https://isofolmedical.com/
- Phone
- +46 317972280
- Auditors
- KPMG AB
Upcoming Events for ISOFOL
Isofol Medical AB (publ) Annual Shareholders Meeting
Q1 2025 Isofol Medical AB (publ) Earnings Release
Q2 2025 Isofol Medical AB (publ) Earnings Release
Similar to ISOFOL
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
FAQ
What is the Isofol Medical AB (publ) share price?
As of Today at 21:22 UTC, shares in Isofol Medical AB (publ) are trading at SEK1.90. This share price information is delayed by 15 minutes.
How has the Isofol Medical AB (publ) share price performed this year?
Shares in Isofol Medical AB (publ) last closed at SEK1.90 and the price had moved by +164.48% over the past 365 days. In terms of relative price strength the Isofol Medical AB (publ) share price has outperformed the FTSE Global All Cap Index by +157.86% over the past year.
What are the analyst and broker recommendations for Isofol Medical AB (publ)?
The overall consensus recommendation for Isofol Medical AB (publ) is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Isofol Medical AB (publ) dividend yield?
Isofol Medical AB (publ) does not currently pay a dividend.
Does Isofol Medical AB (publ) pay a dividend?
Isofol Medical AB (publ) does not currently pay a dividend.
When does Isofol Medical AB (publ) next pay dividends?
Isofol Medical AB (publ) does not currently pay a dividend.
How do I buy Isofol Medical AB (publ) shares?
To buy shares in Isofol Medical AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Isofol Medical AB (publ)?
As of the previous close price of SEK1.90, shares in Isofol Medical AB (publ) had a market capitalisation of SEK306.72m.
Where are Isofol Medical AB (publ) shares listed?
Here are the trading details for Isofol Medical AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ISOFOL
What kind of share is Isofol Medical AB (publ)?
Based on an overall assessment of its quality, value and momentum Isofol Medical AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Isofol Medical AB (publ) share price forecast for 2025?
The analyst consensus target price for shares in Isofol Medical AB (publ) is SEK1.31. That is 31.02% below the last closing price of SEK1.90.
Analysts covering Isofol Medical AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Isofol Medical AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Isofol Medical AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -50.48%.
As of the last closing price of SEK1.90, shares in Isofol Medical AB (publ) were trading -23.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Isofol Medical AB (publ) PE Ratio?
The Isofol Medical AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK1.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Isofol Medical AB (publ)?
Isofol Medical AB (publ)'s management team is headed by:
- Par-Ola Mannefred - CHM
- Jarl Jungnelius - CEO
- Gustaf Albert - CFO
- Roger Tell - CSO
- Karin Ganlov - OTH
- Anna Belfrage - DRC
- Magnus Bjorsne - DRC
- Paula Boultbee - DRC
- Alain Herrera - DRC
- Robert Marchesani - DRC